Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01697527 · ClinicalTrials.gov registry record · Phase 2
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
A Phase 2 study of Malignant Neoplasm, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01697527: Active Phase 2 study of Malignant Neoplasm, sponsored by Jonsson Comprehensive Cancer Center.
NCT01697527 is a Phase 2 study of Malignant Neoplasm that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 6 participants, below the 513-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01697527, a Phase 2 study of Malignant Neoplasm, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial will examine whether genetically reprogramming a patient's disease fighting white blood cells may build an immune response to kill cancer cells that express the NY-ESO-1 protein. In this study, this genetic therapy will be given during a stem cell transplant along with a vaccine therapy. The vaccine will be made using the NY-ESO-1 protein and may help to stimulate the engineered immune response to tumor cells.
Primary Outcome
Will be determined by RECIST 1.1 Criteria on Day +90
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- BIOLOGICAL aldesleukin
- BIOLOGICAL NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
Study Locations (1)
California
- University of California at Los Angeles (UCLA ) - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-11-02 |
| Est. Completion | 2027-11-02 |
| Phase | Phase 2 |
What the registry record for NCT01697527 still lists
NCT01697527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 513-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01697527 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01697527 about?
NCT01697527 is a clinical study titled "Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies". This phase II trial will examine whether genetically reprogramming a patient's disease fighting white blood cells may build an immune response to kill cancer cells that express the NY-ESO-1 protein. In this study, this genetic therapy will be given during a stem cell transplant along with a vaccine ...
What is the current status of trial NCT01697527?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2012-11-02. Estimated completion is 2027-11-02.
What conditions does trial NCT01697527 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT01697527?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cyclophosphamide (DRUG), fludarabine phosphate (DRUG), aldesleukin (BIOLOGICAL), NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL (BIOLOGICAL).
Who is sponsoring clinical trial NCT01697527?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01697527 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01697527's enrollment target sits among peer trials
6 60th of 59 the lowest of 59 other Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Intraoperative Tumor Margin Identification With ICG Dye Imaging
RECRUITING · Phase 2
-
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
RECRUITING · Phase 2
-
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
RECRUITING · Phase 2
-
Dexamethasone in Controlling Dyspnea in Patients With Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI